ATE134624T1 - Acylverbindungen - Google Patents

Acylverbindungen

Info

Publication number
ATE134624T1
ATE134624T1 AT91810098T AT91810098T ATE134624T1 AT E134624 T1 ATE134624 T1 AT E134624T1 AT 91810098 T AT91810098 T AT 91810098T AT 91810098 T AT91810098 T AT 91810098T AT E134624 T1 ATE134624 T1 AT E134624T1
Authority
AT
Austria
Prior art keywords
hydrocarbon
carboxy
cycloaliphatic
aliphatic hydrocarbon
optionally
Prior art date
Application number
AT91810098T
Other languages
German (de)
English (en)
Inventor
Peter Dr Buehlmayer
Franz Dr Ostermayer
Tibur Dr Schmidlin
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25684817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE134624(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of ATE134624T1 publication Critical patent/ATE134624T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Record Carriers (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT91810098T 1990-02-19 1991-02-12 Acylverbindungen ATE134624T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH51890 1990-02-19
CH223490 1990-07-05

Publications (1)

Publication Number Publication Date
ATE134624T1 true ATE134624T1 (de) 1996-03-15

Family

ID=25684817

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91810098T ATE134624T1 (de) 1990-02-19 1991-02-12 Acylverbindungen

Country Status (26)

Country Link
US (2) US5399578A (fr)
EP (1) EP0443983B1 (fr)
JP (1) JP2749458B2 (fr)
KR (1) KR0171409B1 (fr)
AT (1) ATE134624T1 (fr)
AU (1) AU644844B2 (fr)
CA (2) CA2036427C (fr)
CY (2) CY1978A (fr)
DE (4) DE19675036I2 (fr)
DK (1) DK0443983T3 (fr)
ES (1) ES2084801T3 (fr)
FI (2) FI107921B (fr)
GR (1) GR3019155T3 (fr)
HK (1) HK219996A (fr)
HU (2) HU219343B (fr)
IE (1) IE71155B1 (fr)
IL (1) IL97219A (fr)
LU (4) LU90100I2 (fr)
LV (1) LV5773B4 (fr)
NL (3) NL970001I2 (fr)
NO (5) NO2007009I2 (fr)
NZ (1) NZ237126A (fr)
PH (1) PH30484A (fr)
PT (1) PT96799B (fr)
SA (1) SA93140130A (fr)
UY (1) UY23835A1 (fr)

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657498B2 (en) * 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
EP0528762B1 (fr) * 1991-08-15 1997-05-07 Novartis AG Acides aminés N-acyl-N-hétérocyclyl- ou naphtyl-alkyl comme angiotensine II antagonistes
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
US5252753A (en) * 1991-11-01 1993-10-12 Ortho Pharmaceutical Corporation Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
DE69230721T2 (de) * 1991-12-27 2000-08-31 Kyowa Hakko Kogyo Co., Ltd. Tricyclische Verbindungen als Angiotensin-II-Antagonisten
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
US5256658A (en) * 1993-01-15 1993-10-26 Ortho Pharmaceutical Corporation Angiotensin II inhibitors
FR2711367B1 (fr) * 1993-10-19 1995-12-01 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
FI963611A7 (fi) * 1994-03-17 1996-09-13 Novartis Ag Diabeettisen munuaissairauden hoito valsartaanilla
JPH0853424A (ja) * 1994-08-11 1996-02-27 Kureha Chem Ind Co Ltd ベンズイミダゾールスルホン酸アミド誘導体
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
WO1997013513A1 (fr) * 1995-10-06 1997-04-17 Novartis Ag Antagonistes du recepteur d'at1 destines a prevenir et traiter l'insuffisance renale postischemique et a proteger des reins ischemies
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
WO1997030036A1 (fr) * 1996-02-15 1997-08-21 Novartis Ag Derives d'aryle
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
KR19990087063A (ko) 1996-02-20 1999-12-15 스티븐 비. 데이비스 비페닐 이속사졸 술폰아미드의 제조 방법
DK0883401T3 (da) 1996-02-29 2003-05-05 Novartis Ag AT1-receptorantagonist til stimulering af apoptose
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
KR980002035A (ko) * 1996-06-17 1998-03-30 손경식 비페닐 유도체 및 그의 제조방법 및 그를 함유한 약제 조성물
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
WO1998033781A1 (fr) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Procede pour prevenir ou traiter l'hypertension due a une baisse de secretion de la renine, par l'administration d'un antagoniste de l'endotheline
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6271244B1 (en) 1998-06-03 2001-08-07 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
US6274602B1 (en) 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
US6187784B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6187796B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Sulfone hair growth compositions and uses
US6429215B1 (en) 1998-06-03 2002-08-06 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
JP2002516846A (ja) * 1998-06-03 2002-06-11 ジーピーアイ ニル ホールディングス インコーポレイテッド 小分子スルホンアミド発毛組成物および使用
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
BR9815882A (pt) 1998-06-03 2002-09-17 Gpi Nil Holding Inc Sulfonamidas ligadas por n de ácido carboxìlicos n-heterocìclicos ouou de isósteros de ácidos carboxìlicos
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
PT1094816E (pt) * 1998-07-06 2009-03-10 Bristol Myers Squibb Co Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina
ES2552639T3 (es) * 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
TR200805275T2 (tr) * 1998-12-23 2008-09-22 Novartis Ag AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
EP1013273A1 (fr) * 1998-12-23 2000-06-28 Novartis AG Utilisation des antagonistes du recepteur AT-1 ou des modulateurs du recepteur AT-2 pour le traitement de maladies asocciées à une augmentation de recepteurs AT-1 ou AT-2
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
AU3718900A (en) 1999-03-19 2000-10-09 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
JP4374102B2 (ja) * 1999-09-24 2009-12-02 住友化学株式会社 Ｎ，ｎ−ジイソプロピルエチルアミンの分離方法
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
CA2395088A1 (fr) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Company Biphenyl sulfonamides utilises comme doubles antagonistes des recepteurs de l'angiotensine et de l'endotheline
MXPA02006134A (es) 1999-12-21 2002-12-13 Guilford Pharm Inc Compuestos derivados de hidantoina, composiciones farmaceuticas y metodos de uso de los mismos.
IL153428A0 (en) * 2000-06-22 2003-07-06 Novartis Ag Solid valsartan pharmaceutical compositions
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
IL153882A0 (en) * 2000-07-19 2003-07-31 Novartis Ag Valsartan salts
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
EP1354871B1 (fr) * 2000-12-26 2008-02-20 Pola Pharma Inc. Derives de biphenyle
MY133479A (en) * 2001-02-24 2007-11-30 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
RU2004105965A (ru) * 2001-08-28 2005-05-10 Санкио Компани, Лимитед (Jp) Лекарственные композиции, содержащие антагонист рецептора ангиотензина ii
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US20040072886A1 (en) * 2002-04-15 2004-04-15 Dr. Reddy's Laboratories Limited Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan)
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
PL375713A1 (en) 2002-08-19 2005-12-12 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
WO2004031118A1 (fr) 2002-10-03 2004-04-15 Ono Pharmaceutical Co., Ltd. Antagonistes des recepteurs de l'acide lysophosphatidique (lpa)
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
WO2004083192A1 (fr) * 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd. Formes polymorphes de valsartan
EP1950204A1 (fr) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Forme amorphe de valsartan
WO2004087681A1 (fr) * 2003-03-31 2004-10-14 Hetero Drugs Limited Nouvelle forme amorphe du valsartan
US7010633B2 (en) * 2003-04-10 2006-03-07 International Business Machines Corporation Apparatus, system and method for controlling access to facilities based on usage classes
EP1556363A2 (fr) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Procede de preparation du valsartan et de ses intermediaires
EP1618097A1 (fr) * 2003-04-21 2006-01-25 Teva Pharmaceutical Industries Ltd Processus de preparation de valsartan
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CZ298685B6 (cs) * 2003-05-15 2007-12-19 Zentiva, A.S. Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu)
JP4901474B2 (ja) * 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド 置換ピロール誘導体
AU2003245037A1 (en) * 2003-06-16 2005-01-04 Hetero Drugs Limited A novel process for preparation of valsartan
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
EP1658281B1 (fr) * 2003-08-27 2010-09-29 Zentiva, k.s. Procede d'extraction du groupe protecteur de triphenylmethane
US20070238740A1 (en) * 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
JP4537678B2 (ja) * 2003-09-04 2010-09-01 住友化学株式会社 ２’−（１ｈ−テトラゾール−５−イル）ビフェニル−４−カルボアルデヒド結晶およびその製造方法
BRPI0415198A (pt) * 2003-10-10 2006-12-05 Solvay Pharm Gmbh composição farmacêutica compreendendo um agonista seletivo do receptor da imidazolina i1 e um bloqueador do receptor da angiotensina ii
AU2004293013B2 (en) 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
WO2005049587A1 (fr) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Procede de preparation de tetrazole de biphenyle
HRP20030965A2 (en) * 2003-11-24 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of (s)-n-pentanoyl-n-[[2'-(
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
BRPI0508880A (pt) 2004-03-17 2007-09-04 Novartis Ag uso de compostos orgánicos
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
JP4793692B2 (ja) 2004-04-26 2011-10-12 小野薬品工業株式会社 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
CZ298471B6 (cs) * 2004-05-19 2007-10-10 Zentiva, A.S. Soli benzylesteru N-[(2´-(1H-tetrazol-5-yl)bifenyl-4-yl)methyl]-(L)-valinu a jejich použití pro výrobu valsartanu
BRPI0512707A (pt) * 2004-07-02 2008-04-01 Sankyo Co inibidor de produção de fator tecidual
US20080085914A1 (en) 2004-10-08 2008-04-10 David Louis Feldman Use Of Organic Compounds
MX2007005129A (es) 2004-10-27 2007-09-11 Daiichi Sankyo Co Ltd Compuesto de benceno que tiene 2 o mas sustituyentes.
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR20070100717A (ko) 2004-12-22 2007-10-11 이난티아, 에스. 엘. 앤지오텐신 ⅱ 수용기 길항제의 제조를 위한 중간화합물
AU2005318365B2 (en) * 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
US7659406B2 (en) * 2005-01-03 2010-02-09 Dr. Reddy's Laboratories Limited Process for preparing valsartan
TW200637832A (en) * 2005-01-11 2006-11-01 Teva Pharma Process for preparing amorphous valsartan
US20060281801A1 (en) * 2005-04-19 2006-12-14 Ashok Kumar Process for the preparation of valsartan and its intermediates
WO2007017897A2 (fr) * 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
WO2007005967A2 (fr) * 2005-07-05 2007-01-11 Teva Pharmaceutical Industries Ltd. Procede de preparation de valsartan
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AT502219B1 (de) * 2005-08-04 2007-04-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von 5-substituierten tetrazolen
WO2007019448A2 (fr) * 2005-08-08 2007-02-15 Nitromed, Inc. Composes antagonistes de l'angiotensine ii amplifiant l'oxyde nitrique, compositions et methodes d'utilisation associees
JP2009504800A (ja) * 2005-08-22 2009-02-05 アレンビク リミテッド バルサルタンの調製方法
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007057919A2 (fr) * 2005-10-25 2007-05-24 Alembic Limited Procede ameliore pour la preparation de (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
US20080227836A1 (en) * 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan
EP1948599A1 (fr) * 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Procede de preparation de sel hemicalcique d acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20070141533A1 (en) * 2005-12-20 2007-06-21 Ford Christopher W Polymeric dental implant assembly
US20070166372A1 (en) * 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
WO2007088558A2 (fr) * 2006-02-02 2007-08-09 Alembic Limited Procédé de purification du valsartan
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
CN109503584A (zh) * 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
UA91129C2 (ru) 2006-05-09 2010-06-25 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
EP2021000A2 (fr) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
CZ300801B6 (cs) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Kompozice s valsartanem v pevných lékových formách
US20090304797A1 (en) * 2006-06-23 2009-12-10 Tarur Venkatasubramanian Radha Process for the Preparation of Micronized Valsartan
US20080004313A1 (en) * 2006-06-28 2008-01-03 Mai De Ltd. Preparation of crystalline polymorphs of rimonabant hydrochloride
EP2057132A2 (fr) * 2006-07-03 2009-05-13 Aurobindo Pharma Limited Procede ameliore de prparation d'un antagoniste de l'angiotensine ii
AR063469A1 (es) * 2006-07-14 2009-01-28 Ranbaxy Lab Ltd Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
MX2009001963A (es) 2006-08-22 2009-03-30 Ranbaxy Lab Ltd Inhibidores de metaloproteinasa de matriz.
EP1908469A1 (fr) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
EP2097395A1 (fr) * 2006-12-14 2009-09-09 Ratiopharm GmbH Procédé destiné à la préparation de valsartan et produits intermédiaires
BRPI0806700A8 (pt) 2007-01-12 2019-01-22 Novartis Ag processo
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2139473A1 (fr) * 2007-03-29 2010-01-06 Alembic Limited Formulations de comprimés de valsartan
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
US8288561B2 (en) * 2007-05-07 2012-10-16 Cipla Limited Process for preparing valsartan
US20080299218A1 (en) * 2007-06-01 2008-12-04 Protia, Llc Deuterium-enriched valsartan
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP1849777B1 (fr) * 2007-06-07 2008-10-29 Inke, S.A. Procédé pour l'obtention d'un sel de valsartan utile pour l'obtention de valsartan
EP2167477B1 (fr) * 2007-06-27 2013-02-27 Mylan Laboratories Limited Procédé pour préparer du valsartan pur
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
MX2010001821A (es) * 2007-08-17 2010-03-10 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
WO2009035543A1 (fr) 2007-09-07 2009-03-19 Theravance, Inc. Agents antihypertensifs à double action
CN104119336B (zh) * 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
CA2701695A1 (fr) 2007-10-09 2009-04-16 Novartis Ag Formulation pharmaceutique de valsartan
EP2316422A1 (fr) 2007-11-12 2011-05-04 Novartis AG Compositions pharmaceutiques liquides contenant du valsartan
EP2225210B1 (fr) 2007-12-11 2012-04-25 Theravance, Inc. Dérivés de benzimidazole à double effet et leur utilisation en tant qu'antihypertenseurs
MX2010007281A (es) * 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
EP2090567A3 (fr) 2008-02-13 2011-06-01 Ranbaxy Laboratories Limited Processus pour la préparation d'intermédiaires de valsartan
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
WO2009125416A2 (fr) 2008-04-07 2009-10-15 Hetero Research Foundation Procédé de préparation d'un intermédiaire de valsartan
WO2009134741A1 (fr) 2008-04-29 2009-11-05 Theravance, Inc. Agents antihypertenseurs à double action
KR100995734B1 (ko) 2008-05-28 2010-11-19 일동제약주식회사 발사르탄의 개선된 제조방법
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010011821A2 (fr) 2008-07-24 2010-01-28 Theravance, Inc. Agents anti-hypertensifs à double action
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2764251T3 (es) * 2008-08-15 2020-06-02 Boehringer Ingelheim Int Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
CN101362728B (zh) * 2008-08-22 2011-07-20 北京赛科药业有限责任公司 一种缬沙坦的合成方法
WO2010029089A2 (fr) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Polythérapie pour le traitement du diabète et des états pathologiques apparentés
WO2010042714A1 (fr) * 2008-10-10 2010-04-15 Janssen Pharmaceutica Nv Thérapie d’association comprenant des inhibiteurs de récepteur d’angiotensine et antagonistes de récepteur de vasopressine
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2194048A1 (fr) 2008-12-02 2010-06-09 Dirk Sartor Esters de nitrate pour le traitement de maladies vasculaires et métaboliques
KR101012135B1 (ko) 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
EP2382216A1 (fr) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Formes de sel d'un composé organique
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
CN101768128B (zh) * 2009-01-05 2012-10-10 浙江华海药业股份有限公司 一种含10%以上异构体的缬沙坦的精制方法
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN101475540B (zh) * 2009-01-22 2011-05-11 江苏德峰药业有限公司 一种缬沙坦的制备方法
WO2010093601A1 (fr) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
US7956054B2 (en) 2009-07-07 2011-06-07 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
WO2011011232A1 (fr) 2009-07-22 2011-01-27 Theravance, Inc. Agents antihypertenseurs à double action à base d'oxazole
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2316821A1 (fr) * 2009-10-27 2011-05-04 Novartis AG Procédé pour la fabrication de composés organiques
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011090929A1 (fr) 2010-01-19 2011-07-28 Theravance, Inc. Agents antihypertenseurs de thiophène, pyrrole, thiazole et furane à double action
KR101152144B1 (ko) * 2010-02-01 2012-06-15 경동제약 주식회사 발사르탄의 제조 방법 및 이에 사용되는 신규 중간체
WO2011102702A2 (fr) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
EP2542549B1 (fr) 2010-03-03 2016-05-11 Probiodrug AG Inhibiteurs de glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
SI2556059T1 (sl) * 2010-04-07 2014-07-31 Krka, D.D., Novo Mesto Izboljšan proces za pripravo valsartana
CA2796710A1 (fr) 2010-04-19 2011-10-27 Cardiolynx Ag Derives de valsartan portant des donneurs d'oxyde d'azote dans le traitement de maladies vasculaires et metaboliques
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
US8981109B2 (en) 2010-07-02 2015-03-17 Aurobindo Pharma Ltd Process for the preparation of valsartan
TR201005419A2 (tr) 2010-07-05 2012-01-23 B�Lg�� Mahmut Valsartan içeren farmasötik bileşim.
SG187007A1 (en) 2010-08-03 2013-02-28 Novartis Ag Highly crystalline valsartan
CA2806780A1 (fr) 2010-08-23 2012-03-01 Novartis Ag Procede de preparation d'intermediaires pour produire des inhibiteurs de l'endopeptidase neutre (epn)
ES2702529T3 (es) 2010-08-24 2019-03-01 Novartis Ag Una composición farmacéutica para uso en la prevención o tratamiento de la insuficiencia cardíaca en un mamífero que recibe terapia anticoagulante
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012056294A1 (fr) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. Procédé amélioré de préparation de n-pentanoyl-n-[[2'-(1h-tétrazol-5-yl)[1,1'-biphényl]-4-yl]méthyl]-l-valine
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
JP5959066B2 (ja) * 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
FR2977253B1 (fr) 2011-06-30 2013-08-09 Centre Nat Rech Scient Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9522873B2 (en) 2011-08-05 2016-12-20 Dongguk University Industry-Academic Cooperation Foundation Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases
US9446032B2 (en) 2011-08-26 2016-09-20 Wockhardt Limited Methods for treating cardiovascular disorders
AP2014007766A0 (en) 2011-12-15 2014-07-31 Takeda Pharmaceuticals Usa Inc Combination os azilsartan and chlorthlidone for treating hypertension black patients
MX2014007933A (es) 2011-12-26 2014-07-30 Novartis Ag Comprimidos y agentes recubiertos en seco.
WO2013098578A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate
WO2013098576A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique de valsartan à libération immédiate
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN107050020A (zh) 2012-05-01 2017-08-18 特兰斯拉图姆医学公司 用于治疗和诊断致盲性眼病的方法
EP4151218A1 (fr) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptine, dérivé de xanthine en tant qu'inhibiteur de dpp-4, destinée à être utilisée dans le traitement de sirs et/ou de sepsis
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
SI2887961T1 (sl) 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
WO2014118721A1 (fr) 2013-01-30 2014-08-07 Ranbaxy Laboratories Limited Formes dosifiées solides orales pharmaceutiques comprenant du valsartan et du nébivolol
EP2977048A4 (fr) 2013-03-12 2017-04-26 LG Life Sciences Ltd. Préparation de complexe comportant du valsartan et de la rosuvastatine calcique et procédé de fabrication correspondant
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
EP3004138B1 (fr) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
JP2016530282A (ja) 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
SI4321157T1 (sl) 2013-08-26 2025-03-31 Novartis Ag Nova uporaba kombinacije blokatorja receptorja angiotenzina (arb) z nevtralnim zaviralcem endopeptidaze (nepi)
WO2015056219A1 (fr) 2013-10-18 2015-04-23 Ranbaxy Laboratories Limited Procédé de séchage et de micronisation simultanés de valsartan
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072386A (zh) * 2014-06-28 2014-10-01 浙江华海药业股份有限公司 一种缬沙坦中间体的改进方法
WO2016037552A1 (fr) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 Composé cristallin bloqueur de récepteur de l'angiotensine-inhibiteur d'endopeptidase neutre (arb-nepi), son procédé de préparation et son application
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
JP6382736B2 (ja) * 2015-02-02 2018-08-29 株式会社トクヤマ バルサルタンの製造方法
RS64242B1 (sr) 2015-05-11 2023-06-30 Novartis Ag Režim doziranja sakubitril-valsartana za lečenje srčane insuficijencije
EP3302460A1 (fr) 2015-05-29 2018-04-11 Novartis AG Sacubitril et valsartan pour le traitement d'une maladie métabolique
WO2016201238A1 (fr) 2015-06-12 2016-12-15 Teva Pharmaceuticals International Gmbh Formes à l'état solide de valsartan de trisodium : sacubitril
WO2017006254A1 (fr) 2015-07-08 2017-01-12 Novartis Ag Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
WO2017013010A1 (fr) 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulateurs et/ou activateurs de la guanylate-cyclase soluble (sgc) en association avec un inhibiteur de l'endopeptidase neutre (inhibiteur nep) et/ou des antagonistes d'une angiotensine ii et leur utilisation
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
EP4609912A3 (fr) 2016-02-03 2025-11-12 Novartis AG Nouvelle utilisation d'une combinaison de sacubitril et de valsartan
EP4233840A3 (fr) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinaisons de linagliptine et de metformine
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
US10745363B2 (en) 2016-09-02 2020-08-18 Nanjing Noratech Pharmaceuticals Co., Ltd Crystal forms of valsartan disodium salt
CN107056720A (zh) * 2016-12-30 2017-08-18 湖南千金湘江药业股份有限公司 一种缬沙坦的制备和纯化方法
EP3342400A1 (fr) 2016-12-31 2018-07-04 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Composition pharmaceutique comprenant de la valsartane et du chlorthalidone
WO2018153895A1 (fr) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec un inhibiteur de l'endopeptidase neutre et/ou un antagoniste du récepteur de l'angiotensine ii
EP4299120A3 (fr) 2017-07-07 2024-03-06 Boehringer Ingelheim Vetmedica GmbH Telmisartan pour la prophylaxie ou le traitement de l'hypertension chez les chats
MX391562B (es) 2017-07-28 2025-03-21 Synthon Bv Composicion farmaceutica que comprende sacubitril y valsartan
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3498698A1 (fr) 2017-12-15 2019-06-19 Mankind Pharma Ltd Formes solides de valsartan disodium et son procédé de préparation
AU2019252676A1 (en) 2018-04-11 2020-11-26 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
CA3103599A1 (fr) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Procedes de traitement de l'hypertension au moyen d'une composition pharmaceutique de blocage du recepteur de l'angiotensine ii
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
US10548838B1 (en) 2018-12-14 2020-02-04 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
CR20210441A (es) 2019-01-18 2022-03-11 Astrazeneca Ab Inhibidores de la pcsk9 y métodos de uso de los mismos
US11446243B1 (en) 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
ES3048170T3 (en) 2019-12-02 2025-12-09 Harman Finochem Ltd A process for the preparation of highly pure valsartan
EP3939967A1 (fr) 2020-07-15 2022-01-19 KRKA, d.d., Novo mesto Procédé continu pour la préparation de (s)-méthyl n-((2'-cyano-[1,1'-biphényl]-4-yl)méthyl)-n-pentanoylvalinate dans un réacteur à écoulement
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
US12426594B2 (en) 2020-09-24 2025-09-30 Everest Medical Innovation GmbH Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
US12453805B2 (en) 2020-09-24 2025-10-28 Everest Medical Innovation GmbH Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
CN113387805B (zh) * 2021-07-21 2024-01-12 黑龙江立科新材料有限公司 基于烷基重氮盐取代反应的化合物的制备方法
WO2023118482A1 (fr) 2021-12-24 2023-06-29 Sun Chemical Corporation Synergistes d'amine ayant une absorption uv-a
EP4558480A1 (fr) * 2022-07-18 2025-05-28 Celgene Corporation Composés pour le traitement de maladies neurodégénératives
AU2024277852A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
WO2025125409A1 (fr) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Antagoniste du récepteur de l'angiotensine ii pour la prévention de maladies systémiques chez les chats

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973975A (en) * 1962-05-23 1964-11-04 Painton & Co Ltd Improvements in or relating to electric switches
SE307365B (fr) * 1966-05-28 1969-01-07 Yoshitomi Pharmaceutical
US4301169A (en) * 1978-11-14 1981-11-17 Eisai Co., Ltd. Novel imidazole compound and anti-depressing agent containing the same
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4333943A (en) * 1980-04-24 1982-06-08 Miles Laboratories, Inc. Ethyl 3-(3-indolyl)-3-(5-tetrazolyl) propionate compounds used as anti-hypertensive agents
JPS59128376A (ja) * 1983-01-13 1984-07-24 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
EP0142754A2 (fr) * 1983-11-04 1985-05-29 Ferrer Internacional, S.A. Acides benzoiques substitués sur la position 2, ayant un groupe imidazolyl, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
US4578386A (en) * 1984-02-10 1986-03-25 Usv Pharmaceutical Corp. 7,8-Dihydroimidazo[1,5-a]pyrazin-8-ones
US4755518A (en) * 1985-12-20 1988-07-05 Warner-Lambert Company Imidazolyl or tetrazolyl substituted benzoic acid derivatives and pharmaceutical compositions thereof
US4748245A (en) * 1986-03-20 1988-05-31 Stauffer Chemical Company Process for making phenylthiopyrimidines
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (fr) * 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
ZA875052B (en) * 1986-07-11 1989-03-29 Du Pont Angiotensin ii receptor blocking imidazoles
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4870186A (en) * 1987-05-22 1989-09-26 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4874867A (en) * 1987-05-22 1989-10-17 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4921632A (en) * 1987-08-26 1990-05-01 Nec Corporation Liquid crystal compounds and compositions
US5189048A (en) * 1988-01-07 1993-02-23 E. I. Du Pont De Nemours And Company Substituted 1,2,3 triazole angiotensin II antagonists
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA1338238C (fr) * 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (fr) * 1989-05-15 1990-12-05 Merck & Co. Inc. Benzimidazoles substitués comme antagoniste d'angiotensine II
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
EP0403159B1 (fr) * 1989-06-14 2000-03-01 Smithkline Beecham Corporation Acides imidazoalcénoiques
CA2018443A1 (fr) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Acides imidazolyl-alkenoiques
KR950009860B1 (ko) * 1989-06-30 1995-08-29 이. 아이. 듀퐁 드 네모아 앤드 캄파니 융합된 환 아릴 치환된 이미다졸과 약제학적으로 허용되는 이의 염, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물
DE69025473T2 (de) * 1989-06-30 1996-10-17 Du Pont Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
US5164407A (en) * 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
EP0409332A3 (en) * 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
DE69024556T2 (de) * 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
DE69013607T2 (de) * 1989-08-02 1995-03-02 Takeda Chemical Industries Ltd Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung.
FI903966A7 (fi) * 1989-08-11 1991-02-12 Ici Plc Typpiyhdisteitä
US5100897A (en) * 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5298518A (en) * 1989-09-29 1994-03-29 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
AU640417B2 (en) * 1989-10-25 1993-08-26 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles
IL96019A0 (en) * 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2028925A1 (fr) * 1989-11-06 1991-05-07 Gerald R. Girard Derives substitues de la n-(imidazolyl)alkylalanine
PT95899A (pt) * 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
IE903911A1 (en) * 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
EP0430709A3 (en) * 1989-12-01 1992-02-12 Glaxo Group Limited Benzthiophen derivatives
US5104891A (en) * 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0434038A1 (fr) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Dérivés condensés d'imidazole, leur préparation et leur utilisation
TW201738B (fr) * 1990-03-20 1993-03-11 Sanofi Co
EP0522038A4 (en) * 1990-03-30 1993-05-26 Merck & Co. Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides

Also Published As

Publication number Publication date
US5399578A (en) 1995-03-21
UY23835A1 (es) 1995-03-21
FI107921B (fi) 2001-10-31
DE59107440D1 (de) 1996-04-04
KR910021387A (ko) 1991-12-20
IL97219A (en) 1995-12-08
DK0443983T3 (da) 1996-03-18
EP0443983B1 (fr) 1996-02-28
NL980036I1 (nl) 1999-02-01
LV5773B4 (lv) 1997-04-20
DE122010000024I1 (de) 2010-07-08
NZ237126A (en) 1994-11-25
DE122007000050I1 (de) 2007-11-08
JP2749458B2 (ja) 1998-05-13
NO1998024I1 (no) 1998-10-21
CA2232775A1 (fr) 1991-08-20
HU9802895D0 (en) 1999-02-01
IE910548A1 (en) 1991-08-28
DE19675036I2 (de) 2004-10-21
ES2084801T3 (es) 1996-05-16
FI980787A7 (fi) 1998-04-06
LU91676I2 (fr) 2010-06-07
CA2036427C (fr) 1998-12-29
CA2036427A1 (fr) 1991-08-20
IL97219A0 (en) 1992-05-25
NO2007009I1 (no) 2007-07-23
GR3019155T3 (en) 1996-05-31
PT96799B (pt) 1998-09-30
HU9100537D0 (en) 1991-09-30
AU7115191A (en) 1991-08-22
AU644844B2 (en) 1993-12-23
NO2010008I1 (no) 2010-05-03
CY1978A (en) 1997-09-05
NL300285I1 (nl) 2007-10-01
NO304023B1 (no) 1998-10-12
CY2010009I1 (el) 2010-07-28
HU219343B (en) 2001-03-28
CY2010009I2 (el) 2010-07-28
LV5773A4 (lv) 1996-12-20
PH30484A (en) 1997-05-28
NO910630D0 (no) 1991-02-18
LU91347I2 (fr) 2009-01-14
CA2232775C (fr) 2003-06-10
NL970001I2 (nl) 1997-06-02
IE71155B1 (en) 1997-01-29
EP0443983A1 (fr) 1991-08-28
FI910747A7 (fi) 1991-08-20
FI910747A0 (fi) 1991-02-15
KR0171409B1 (ko) 1999-02-01
HUT61271A (en) 1992-12-28
LU90362I2 (fr) 1999-05-10
US5965592A (en) 1999-10-12
LU90100I2 (fr) 1997-09-25
HU220073B (hu) 2001-10-28
NO1999001I2 (no) 2007-04-23
NL970001I1 (nl) 1997-03-03
PT96799A (pt) 1991-10-31
FI980787A0 (fi) 1998-04-06
FI980787L (fi) 1998-04-06
NO2007009I2 (no) 2010-09-13
NL980036I2 (nl) 2001-02-01
NO910630L (no) 1991-08-20
JPH04235149A (ja) 1992-08-24
HK219996A (en) 1997-01-03
SA93140130A (ar) 2005-12-03
SA93140130B1 (ar) 2005-10-16

Similar Documents

Publication Publication Date Title
DE59107440D1 (de) Acylverbindungen
MY116542A (en) New inhibitors of platelet aggregation.
SE9301911D0 (sv) New peptide derivatives
IL122291A0 (en) Diazepinoindoles their preparation and use
BG103329A (en) Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumour agents
ES536414A0 (es) Procedimiento para preparar la n-(3-trifluorometilfenil)-n'-propargil-piperazina
HUP9701381A2 (hu) Új 7,8-dihidro-8,8-diszubsztituált-9H-1,3-dioxolo-[4,5-h][2,3]-benzodiazepin-származékok, ilyen hatóanyagot tartalmazó gyógyászati készítmény, és eljárás a hatóanyag előállítására
HUP9701380A2 (hu) Új 8-szubsztituált-9H-1,3-dioxolo-[4,5-h][2,3]-benzodiazepin-származékok, ilyen hatóanyagot tartalmazó gyógyászati készítmény, és eljárás a hatóanyag előállítására